Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA https://t.co/Vhx717rw5T https://t.co/OBMdjsegIq

🔎 Take a look at the long-term safety of a JAKi in patients with rheumatic disease in clinical trial and real-world settings Explore the outcomes across >21,000 patient-years: https://t.co/SJQcI26W51 Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Jc0LaJE9zj

Obesity care is about More than the Meds. Join us TONIGHT for the final webinar in our obesity series, exploring what comprehensive obesity care can look like in rheumatology practice. Featuring: Dr. Alvin Wells Dr. Alexis Ogdie Dr. Jack Cush 📅 Sept. 29 | ⏰ 6 PM CT From https://t.co/wDA2RWHkeA

Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications https://t.co/OYTXD4KV6O

Long-term F/U of T2T Artic trial. 230 DMARD naive pts, 84% ACPA+ 179 (82%) in 10 yr F/U & 82% were in DAS < 1.6 remission 10 yrs later w/ only 17% w/ Xray progression. ~50% on csDMARDs, 30% on bDMARDs. Early aggressive works! https://t.co/ASRrIZqfS5 https://t.co/SykEI4QjPa

Residual steroids doesnt preserve remission. Japan FRANK #RA registry 411/3,863 were in Boolean remission - 130 on GC vs 231 non-GC (1/3 on b/tsDMARDs). Roughly 1/3 flared to LDA @12 mos. Outcomes same for GC vs non-GC Rx pts. https://t.co/xPctEjFCLT https://t.co/YIHFaQkzeO

J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/2Tdg96rWFX

Scleroderma-Specific Autoantibodies in Early Systemic Sclerosis Prognostication is tenous in early scleroderma, especially in those with dcSSc. dcSSc has associated with substantial morbidity and disease-specific mortality. Analysis of an early SSc registry shows that anti-RNA https://t.co/Qvu2vSShcg

Obesity and Psoriatic Disease Obesity is a clinically important comorbidity in psoriasis (PsO) and psoriatic arthritis (PsA). Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic https://t.co/WVIqfq8vEj

Gabapentin Use Rose as Restrictions Fell, Study Shows Gabapentin use jumped quickly in Michigan after the drug was removed from the state's controlled substance schedule in 2024, a cross-sectional study showed. https://t.co/xQ9MHqnNxB https://t.co/ipOWS4K61U

Retrospective review of 33 referred pts w/ Recurrent fever w/ MSK & skin Sxs, assessed by NGS. NLRP1 had FMF-like Dz; NLRP recurrent fevers w/ mucocutaneous; NLRP12 periodic fevers w/ MP/EN rash; NLRC4 episodic systemic inflammation GI Sxs & atypical skin rash https://t.co/Ll2V0Uzfio

FDA has approved baricitinib (Olumiant) for the treatment of pediatric patients 12 years of age and older with severe alopecia areata https://t.co/OTXXQvNruw https://t.co/xrg5ocWyjo

Prescribing New GLP-1-Based Therapies https://t.co/cpxyxBMZ8s https://t.co/yV8Jvkh2sk